In this study, our results demonstrated that treatment with NT1014 modifies the phenotype of ovarian cancer cells from a mesenchymal to an epithelial phenotype as evidenced by increased expression of the epithelial marker E-cadherin and decreased expression of the mesenchymal marker Slug. This evidence concerns the gene CDH1 and ovarian carcinoma.